Catalent (CTLT) Tops Q1 EPS by 5c, Revenues Beat; Raises FY21 Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Catalent, Inc. Reports First Quarter Fiscal 2021 Results
November 3, 2020 7:15 AM ESTÂ Q1'21 net revenue of $845.7 million increased 27% as-reported, or 26% in constant currency, compared to Q1'20. On an organic basis, constant currency net revenue in Q1'21 grew 20% compared to Q1'20. Â Q1'21 Adjusted EBITDA of $174.4 million increased 37% as-reported, or 35% in constant currency, compared to Q1'20. Q1'21 Biologics segment net revenue of $377.1 million doubled compared to Q1'20. Net debt leverage of 2.6x as of September 30; more than $1 billion in cash and cash equivalents on-hand at September 30. Increased... More
